Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Top Biologic Industry Leaders to Convene at Biologics World Korea 2013

Published: Friday, December 07, 2012
Last Updated: Friday, December 07, 2012
Bookmark and Share
Bringing together biologics drug innovators and bioprocess professionals from all around the world to discuss strategies in biosimilar and biobetter development, as well as cutting-edge advances in bioprocessing and bioanalytics.

The global biologics market is valued at an estimated US$149 bn and is expected to reach $230 bn by 2015. Monoclonal antibodies (mAbs) representing 32% of the market share is expected to be the fastest growing segment at 12.4% CAGR. South Korea’s biologics industry is well positioned to tap into this growing market. While Celltrion, Samsung Biologics and LG Life Sciences are grabbing the international headlines, innovative firms in South Korea such as Genexine, PharmAbcine, Alteogen and Ildong are building up an impressive innovative biologic pipeline that can rival international players.

The biologics landscape in South Korea is evolving fast. Knowing the who's and understanding the how's of the industry are crucial to stay competitive. Biologics World Korea 2013 conference will convene all these biologic players from South Korea and around the globe, to discuss the trend and challenges in biologic drug development. The conference will be chaired by Dr Byeong Doo Song, the President of Scripps Korea Antibody Institute.

The conference Keynote speaker is Dr Stanley Hong, the President of R&D of Celltrion, who led the first mAb biosimilar approval in the world. He said that the company will be interested in developing Biobetters. The company just launched its product, RemsimaTM worldwide and has already signed several distribution agreements with several leading pharma companies.

Another featured speaker is Dr Paul Coleman, the CEO of Hanwha Biologics, who successfully led the company in making its first landmark deal to license its newly developed biosimilar compound to Merck. Dr Coleman said that a key criterion in making a biosimilar globally available through partnerships is having the highest standards of quality in all aspects of the research and development processes. This is the key to success for the interest of companies who can access global markets. Hanwha Biologics has already garnered the interest of top companies in the world for its portfolio of other biosimilar compounds and is seeking to expand through further research and development of future biosimilar candidates.

The 2013 conference programme features industry visionary presentations from the Celltrion, Hanwha Biologics, Green Cross, Genexine, SK Chemicals, CJ CheilJedang, Mogam Biotech Institute, UCB Korea, Neopharm, KAIST, KRIBB, KBSI, PhamAbcine, Creagene, Merck Serono (USA), Protein Science Corporation (USA), NovImmune (Switzerland), Actokine (USA), Quest Pharma Tech (Canada), Wuxi AppTech Biologics (China) and many more. The conference programme runs on April 16-18 2013 at Sheraton Incheon Hotel. Technology providers such as BD Bioscience, Waters Korea, Dong-Il Shimadzu, Agilent Technologies and many others will also be there to showcase the latest solutions.

Since the inaugural success of Biologics World Korea 2012, the year 2013 conference will be more comprehensive to include biologic players at various stages of development. In the near term future, the innovations and partnerships will continue to drive the activities in this industry. With networking opportunities, presentation of valuable case studies and interactive discussion, the Biologics community can look forward to a fruitful gathering at the Biologics World Korea 2013. This conference aims to capture a holistic view of the issues challenging the industry, from market landscape to regulatory strategy, from bioprocessing to bioanalytics, from antibody engineering to clinical development.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Drug Might Help Treat Sepsis
A DNA enzyme called Top1 plays a key role in turning on genes that cause inflammation in mouse and human cells in response to pathogens. A drug blocking this enzyme rescued mice from lethal inflammatory responses, suggesting a potential treatment for sepsis.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!